Sana Biotechnology, Inc. Share Price & Technical Analysis
SANA · $3.07 (-2.54%)
Healthcare / Biotechnology
$3.07
-2.54%
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-6% return in May, 4% avg return in past 3 year May month.
-21% return in 2026, 56% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -5% | -27% | 10% | -6% | – | – | – | – | – | – | – | -21% |
| 25 | 100% | -16% | -35% | 19% | 16% | 23% | 46% | -21% | 17% | 40% | -12% | -2% | 174% |
| 24 | 34% | 82% | -13% | -10% | -17% | -28% | 13% | 0% | -30% | -17% | -20% | -43% | -48% |
| 23 | 15% | -18% | -11% | 66% | 13% | 0% | -2% | -9% | -28% | -23% | 37% | 0% | 41% |
| 22 | -44% | -27% | 30% | -10% | -32% | 23% | 5% | 3% | -10% | -6% | -15% | -22% | -105% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$886.92M
P/E ratio
—
52W high
$6.55
52W low
$1.98
Volume
41,91,412
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Sana Biotechnology, Inc. share price today?
- Sana Biotechnology, Inc. (SANA) last traded around $3.07 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SANA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SANA. Download the app for real-time alerts.
- How can I analyze Sana Biotechnology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.